Medical devices, healthcare technology and the business of care
510(k) clearance · K263054

BIOFIRE Respiratory Panel 2.1 (RP2.1)

Biofire Diagnostics · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONK263054

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for K263054 on September 22, 2026, covering the BIOFIRE Respiratory Panel 2.1 (RP2.1) from Biofire Diagnostics, a Class II device under 21 CFR 866.3981 with product code QOF in the Microbiology panel. The submission was a Special 510(k) received September 1, 2026, filed against the submitter's own previously cleared RP2.1 (DEN200031).

The cleared change is a pouch module software update that expands the melting temperature window for the Parainfluenza virus 3 target analyte, prompted by post-market identification of a PIV3 sequence variant with Tm values outside prior interpretation criteria. The decision summary states the indications for use and fundamental scientific technology are unchanged, and that reanalysis of clinical and analytical data with the modified software showed performance consistent with the previously cleared device. The review document does not disclose the numeric Tm window, variant prevalence, or reanalysis results.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Sep 22, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K263054
Regulatory pathway
510(k) premarket notification
Product code
QOF
Decision code
SESE
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.

Product code
QOF
FDA device class
2

FDA decision timeline

  1. K263054 received

    Application receipt date recorded by FDA.

  2. K263054 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QOF

Product / regulatory recordCompanyPathwayDecision dateSource
GenMark Diagnostics, Inc.510(k) clearanceOct 30, 2026FDA
Cepheid510(k) clearanceOct 22, 2026FDA
Cepheid510(k) clearanceOct 2, 2026FDA
Cepheid510(k) clearanceSep 25, 2026FDA
Baebies, Inc.510(k) clearanceSep 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biofire Diagnostics

Headquarters
Not reported
Brand website
biofiredx.com
FDA applicant address
Salt Lake City, UT

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records